BrightPath Biotherapeutics Co., Ltd.JP:4594
| Mar 31,
2015 | Mar 31,
2016 | Mar 31,
2017 | Mar 31,
2018 | Mar 31,
2019 | Mar 31,
2020 | Mar 31,
2021 | Mar 31,
2022 | Mar 31,
2023 | Mar 31,
2024 |
|---|
| Profit (loss) before income taxes | -408 | -993 | -1,117 | -1,573 | -1,881 | -1,860 | -1,717 | -1,482 | -1,484 | -1,166 |
|---|
| Depreciation | 9 | 19 | 42 | 73 | 83 | 62 | 67 | 35 | 17 | 0 |
|---|
| Impairment losses | - | - | - | - | 195 | 48 | 10 | 6 | 10 | 7 |
|---|
| Increase (decrease) in provision for retirement benefits | 2 | 4 | - | - | 2 | 11 | -11 | -0 | 2 | 3 |
|---|
| Interest and dividend income | -0 | -0 | -0 | -0 | -2 | -0 | -0 | -0 | -0 | -0 |
|---|
| Interest expenses on bonds | - | - | - | - | - | - | - | 0 | 0 | - |
|---|
| Decrease (increase) in trade receivables | 33 | -27 | 52 | -22 | 76 | 0 | 0 | -16 | 17 | 0 |
|---|
| Increase (decrease) in trade payables | -42 | 8 | -41 | -14 | 20 | -28 | -0 | 1 | -2 | -0 |
|---|
| Other, net | -9 | 20 | -35 | -102 | -17 | -4 | -83 | -48 | 238 | 1 |
|---|
| Subtotal | -529 | -921 | -1,078 | -1,588 | -1,468 | -1,782 | -1,767 | -1,509 | -1,202 | -1,155 |
|---|
| Interest and dividends received | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|---|
| Interest paid | - | - | - | - | - | - | - | -0 | -0 | - |
|---|
| Income taxes paid | -2 | -2 | -2 | -3 | -4 | -2 | -3 | -2 | -2 | -2 |
|---|
| Net cash provided by (used in) operating activities | -447 | -909 | -1,068 | -1,591 | -1,458 | -1,784 | -1,770 | -1,512 | -1,204 | -1,157 |
|---|
| Purchase of property, plant and equipment | -41 | -23 | -97 | -108 | -173 | -107 | -35 | -18 | -1 | -6 |
|---|
| Purchase of intangible assets | -2 | -10 | -7 | -3 | -2 | -3 | -0 | - | -1 | -1 |
|---|
| Net cash provided by (used in) investing activities | -67 | -32 | -97 | -112 | -185 | -107 | -36 | -18 | -2 | -8 |
|---|
| Proceeds from issuance of shares resulting from exercise of share acquisition rights | - | - | 3,514 | 3,269 | 16 | 11 | 2,053 | 478 | 520 | 573 |
|---|
| Proceeds from issuance of bonds | - | - | - | - | - | - | - | 300 | - | 500 |
|---|
| Redemption of bonds | - | - | - | - | - | - | - | -212 | -87 | -387 |
|---|
| Purchase of treasury shares | - | - | - | - | - | - | - | - | - | - |
|---|
| Proceeds from issuance of share acquisition rights | - | - | 45 | 12 | - | - | 1 | 4 | - | 5 |
|---|
| Net cash provided by (used in) financing activities | 1,248 | 2,673 | 3,559 | 3,281 | 16 | 9 | 2,053 | 569 | 432 | 691 |
|---|
| Net increase (decrease) in cash and cash equivalents | 734 | 1,732 | 2,395 | 1,578 | -1,627 | -1,883 | 247 | -960 | -774 | -474 |
|---|